A groundbreaking study from Boston University's CTE Center may soon enable the diagnosis of chronic traumatic encephalopathy (CTE) in living individuals through a simple blood test. Previously, definitive CTE diagnosis was only possible through post-mortem examination of brain tissue.

The research, published in the Journal of the American Medical Association, identifies a specific tau protein, eMTBR-tau, as a potential biomarker for the disease. In the study, researchers analyzed blood samples from 21 former football players whose brains had been autopsied. They found significantly higher levels of eMTBR-tau in those with late-stage CTE.

Dr. Gil Rabinovici, a neurologist at UC San Francisco and co-author of the study, described the finding as a potential game-changer. "This is really a game changer because it is the first time that we have a test that is possible to give to living people that can detect this pathology," Rabinovici told The Post. He noted that previous attempts to diagnose CTE in living individuals using imaging and spinal fluid tests had not yielded clear signals.

CTE has been linked to repeated blows to the head, most notably in athletes who participate in contact sports like American football. A recent study indicated that three-quarters of more than 2,300 former NFL players examined showed signs of late-stage CTE. The disease has been associated with behavioral changes and cognitive decline, as seen in cases like former NFL players Junior Seau and Dave Duerson.

While Rabinovici cautioned that the findings are preliminary and require replication, he expressed optimism about their implications. "When you see the kind of data that we have in this paper, the finding is so clear and the implications are so apparent, that’s why you get goosebumps," he said.

The potential for a reliable diagnostic test could significantly advance research into CTE. It may allow for clinical trials of potential treatments, which have been hindered by the inability to diagnose the disease in living patients. "This may unlock the possibility of having clinical trials and testing some of these promising therapies," Rabinovici explained.

Researchers are already planning further trials to validate the blood test. In addition to examining brain banks globally, they have recruited over a hundred living football players for the next phase of their research project, with participants agreeing to donate their brains for posthumous examination. The team aims to correlate blood test results with known indicators of CTE, such as cognitive impairment and brain atrophy observed in scans.

"I think there’s a lot more that’s going to come in the next year or two to validate this and hopefully bring it into the clinic," Rabinovici added. This development could lead to a better understanding of CTE's prevalence, risk factors, and potential protective elements, while also offering individuals peace of mind and a path toward potential treatment.